Tesamorelin — 20 mg

About Tesamorelin

Human randomized trial · Specific clinical population

What it is studied for

A growth hormone-releasing hormone analogue studied in pituitary signaling and visceral-fat metabolism.

What selected research found

A 2014 randomized trial in people with HIV and abdominal fat accumulation reported reductions in visceral and liver fat. Early fasting-glucose increases also occurred.

Evidence limits

Results in that specific population are not evidence for general weight-loss use, and do not establish equivalence of this catalog material to a clinical formulation.

Selected sources

1. Stanley et al., 2014 — Randomized clinical trial ↗

References reviewed October 10, 2026.

Research use only. These notes summarize selected publications; they are not a systematic review, medical advice, dosing instructions, or evidence about this product lot. Clinical studies used controlled study formulations and supervision. AuraBio materials are not for human or veterinary use. Review the exact material identity and available lot documentation for your laboratory application.